Therapeutic Response

Wild type KRAS and Wild type NRAS status confers therapeutic sensitivity to Panitumumab in patients with Colorectal Adenocarcinoma.

Statements

Source and description
Vectibix (panitumumab) [product information]. EMA. The European Medicines Agency (EMA) has authorized panitumumab as a monotherapy for the treatment of adult patients with wild-type RAS metastatic colorectal cancer (mCRPC) after failure of fluoropyrimidine-, oxaliplatin-, and irinotecan-containing chemotherapy regimens. Panitumumab's product information further states that evidence of wild-type RAS (KRAS and NRAS) status is required before initiating treatment with panitumumab and that mutational status should be deteremined by an experienced laboratory using validated test methods for detection of KRAS (exons 2, 3, and 4) and NRAS (exons 2, 3, and 4) variants.
Panitumumab 6mg/kg Therapy. NCCP National SACT Regimen. HSE. The Republic of Ireland's Health Service Executive (HSE) has approved panitumumab for reimbursement as a monotherapy treatment option for the treatment of wild-type RAS metastatic colorectal cancer (mCRC) after failure of fluoropyrimidine, oxaliplatin, and irinotecan containig chemotherapy regimens in adult patients. The European Medicine Agency's product information for Vectibix (panitumumab) defines RAS wild type as considering mutational status of KRAS and NRAS exons 2, 3, and 4, and that mutational status should be determined by an experienced laboratory using validated test methods.